STAT3 and medulloblastoma: In long-term analysis we demonstrated for the first time that Pazopanib and Sorafenib not only reduced STAT3 phosphorylation but also significantly decreased STAT3 protein levels in 3 of 4 medulloblastoma lines whilst levels of the housekeeping protein endoplasmatic reticulum-golgi intermediate compartment 53 (ERGIC53) and beta-tubulin respectively remained stable.